References
- Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–27
- Boxenbaum H. (1984). Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 15:1071–121
- Boxenbaum H, Ronfeld R. (1983). Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 245:R768–75
- Bysted BV, Scharling B, Møller T, Hansen BL. (2007). A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia 13:527–32
- Dedrick R, Bischoff KB, Zaharko DS. (1970). Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 54:95–101
- Elm T, Karpf DM, Øvlisen K, et al. (2012). Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. Haemophilia 18:139–45
- Karpf DM, Sørensen BB, Hermit MB, et al. (2011a). Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa. Thromb Res 128:191–5
- Karpf DM, Kjalke M, Thim L, et al. (2011b). Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs. Haemophilia 17:e963–8
- Keith JC, Ferranti TJ, Misra S, et al. (1995). Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. Thromb Haemost 73:101–5
- Lambert T, Recht M, Valentino LA, et al. (2007). Reformulated BeneFIX: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 13:233–43
- Mahmood I. (2005a). Interspecies scaling of clearance. In:Interspecies pharmacokinetic scaling: principles and application of allometric scaling. Rockville (MD): Pine House Publishers, 39–85
- Mahmood I. (2005b). First-in-human dose selection. In: Interspecies pharmacokinetic scaling: principles and application of allometric scaling. Rockville (MD): Pine House Publishers, 259–87
- Mahmood I. (2009). Pharmacokinetic allometric scaling of coagulation factors and tissue-type plasminogen activators. Haemophilia 15:1109–17
- Mahmood I. (2013). Prediction of drug concentration-time profiles of therapeutic proteins in humans from animals. Xenobiotica 43:153--60
- Mahmood I, Goteti K. (2012). Prediction of drug concentration-time data in humans from animals: a comparison of three methods. Xenobiotica 42:756–65
- Mahmood I, Yuan R. (1999). A comparative study of allometric scaling with plasma concentrations predicted by species-invariant time methods. Biopharm Drug Dispos 20:137–44
- Martinowitz U, Bjerre J, Brand B, et al. (2011). Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) – an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia 17:854–9
- McCarthy K, Stewart P, Sigman J, et al. (2002). Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost 87:824–30
- Mordenti J. (1985). Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data. J Pharm Sci 74:1097–9
- Møss J, Rosholm A, Laurén A. (2011). Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects. J Thromb Haemost 9:1368–74
- Swabb EA, Bonner DP. (1983). Prediction of aztreonam pharmacokinetics in humans based on data from animals. J Pharmacokinet Biopharm 11:215–23
- Wajima T, Yano Y, Fukumura K, Oguma T. (2004). Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci 93:1890–900